This clinical-stage specialty pharmaceutical company recently released positive clinical data and could be ready to move higher. Taiwan Liposome Co. Ltd. (NASDAQ: TLC) engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs).
The company’s BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury, and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
Cantor Fitzgerald recently started coverage, noting that the company’s expertise and experience with liposome science has yielded the BioSeizer and NanoX formulation technologies that have the potential to improve the pharmacologic and therapeutic potential of approved pharmacophores to treat various medical disorders.
Cantor Fitzgerald’s price target is set at $11. The consensus price objective is also $11, and the stock closed on Friday at $5.95 a share.
This company faces more and more competition, but it soon will merge with a big satellite provider. Pandora Media Inc. (NYSE: P) provides internet music streaming services in North America. It allows its listeners to create personalized stations to access free music and comedy catalogs, as well as a personalized playlist generating system.
The company also offers Pandora One, a paid subscription service to listeners. And it sells audio, display and video advertising to advertisers for delivery on computer, mobile and other connected device platforms.
Late in December, Sirius XM announced that a definitive proxy statement/prospectus has been filed with the U.S. Securities and Exchange Commission in connection with its pending merger with Pandora Media. Pandora’s special meeting of stockholders to vote on the transaction is scheduled to be held on January 29, 2019. Stockholders of record as of the close of business on November 30, 2018, will be entitled to vote at the special meeting in person or by proxy.
B. Riley FBR has a Buy rating on the shares with an $11.50 price target. The consensus target is $9.41, and the stock ended last week at $8.76.
This off-the-radar company has seen a ton of fourth-quarter volatility but has big upside potential. Verra Mobility Corp. (NASDAQ: VRRM) engages in the development of transportation solutions. It focuses on safety camera enforcement, safety and data analysis, parking solutions, rental fleet toll management and red light enforcement.
Verra Mobility maintains its leadership position in the marketplace through meaningful scale and has demonstrated consistent revenue growth underscored by its differentiated transaction processing model.
Until recently, Verra Mobility was known as American Traffic Solutions. It was rebranded following the acquisitions of Highway Toll Administration and Euro Parking Collection, transactions that helped transform the business into a global enterprise with a broad range of transportation technology solutions. Verra Mobility is headquartered in Mesa, Arizona, and currently operates in 15 countries.
The $14 Deutsche Bank price target comes with a Buy rating and is the same as the consensus target. The shares were last seen trading at $9.45.
Five stocks for aggressive accounts that look to get shares count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage on them.